Heron Bay Capital Management bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) during the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 30,284 shares of the company’s stock, valued at approximately $16,038,000. Medpace accounts for about 1.5% of Heron Bay Capital Management’s portfolio, making the stock its 23rd biggest holding.
Other hedge funds have also made changes to their positions in the company. Johnson Financial Group Inc. acquired a new position in shares of Medpace during the 2nd quarter worth $27,000. Geneos Wealth Management Inc. grew its stake in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Elyxium Wealth LLC acquired a new stake in Medpace in the 4th quarter valued at about $30,000. Allied Private Wealth LLC purchased a new position in Medpace during the 2nd quarter valued at about $31,000. Finally, Kilter Group LLC purchased a new position in Medpace during the 2nd quarter valued at about $31,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.
Insiders Place Their Bets
In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the completion of the sale, the vice president directly owned 62,984 shares of the company’s stock, valued at $37,790,400. The trade was a 10.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 122,261 shares of company stock valued at $71,729,129. 20.50% of the stock is currently owned by insiders.
Medpace Trading Up 1.3%
Medpace (NASDAQ:MEDP – Get Free Report) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same period in the prior year, the firm earned $3.10 EPS. The firm’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.
Analyst Ratings Changes
A number of equities analysts have issued reports on the stock. TD Cowen lifted their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Truist Financial raised their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Barclays set a $600.00 target price on Medpace in a research note on Thursday, July 23rd. Finally, Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Three research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $584.18.
Get Our Latest Stock Report on Medpace
Medpace Company Profile
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Read More
- Five stocks we like better than Medpace
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
